Transplantations are a routine method of treatment of chronic and acute organ failure. Changes in the therapeutic strategy led to improvement of organ and patient survival immediately after transplantation and during the early post-transplantation period. Medium-term and long-term results of organ survival improved less markedly. Chronic dysfunction and death are the most frequent causes of loss of a transplanted organs one year after transplantation. Chronic dysfunction has immunological and non-immunological causes. An important risk factor is hyperlipidaemia. Therapy must be started as soon as possible. It threatens the patients prognostically more than the normal population. Dietetic treatment and optimal immunosuppression are essential therapeutic steps which have a favourable effect on the general prognosis. A great hope in transplantology are statins. They have not only a positive effect on blood lipids but also an immunosuppressive and antiproloferative effect which is very favourable for the prevention of transplantation vasculopathies. Most probably their group effect is involved. Statins combined with classical immunosuppressive preparations reduce the incidence of acute rejections. The effect on lipid levels, the frequency of rejections and development of vasculopathies makes statins important adjuvant preparations in transplantology.

Keywords: Graft Survival; Humans; Hyperlipidemias /drug therapy/; Lipid Metabolism; Organ Transplantation /adverse effects/; Prognosis; Risk Factors; Vascular Diseases /etiology/